Editorial Comment to Efficacy and safety of tadalafil 5 mg once‐daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phase 3, randomized, double‐blind, parallel, placebo‐ and tamsulosin‐controlled study
Abstract
in FY 2013. [Cited 2 Apr 2018]. Available from URL: https://www.pmda.go. jp/files/000153463.pdf 11 Food and Drug Administration, Ministry of Health and Welfare. Western medicine, medical equipment, cosmetic license inquiry. Taiwan. [Cited 12 Apr 2018]. Available from URL: https://www.fda.gov.tw/MLMS/(S(mvtpp m45djhij2rtyi04r2uq))/H0001D.aspx?Type=Lic&LicId=02025147 12 PRNewswire (Oct. 30, 2012). European Commission approves Cialis (tadalafil) tablets for the treatment of the signs and symptoms of benign prostatic hyperplasia. [Cited 18 Jan 2018]. Available from URL: http://lilly.medi aroom.com/index.php?s = 9042&item=134991 13 Kim SC, Park JK, Kim SW et al. Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo-controlled pilot study using tamsulosin as an active control. Low. Urin. Tract. Symptoms 2011; 3: 86–93. 14 Takeda M, Nishizawa O, Imaoka T, Morisaki Y, Viktrup L. Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia: results from a 12-week placebo-controlled dose-finding study with a 42-week open-label extension. Low. Urin. Tract. Symptoms 2012; 4: 110–9. 15 Kawabe K, Yoshida M, Homma Y; Silodosin Clinical Study Group. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 12 participants or records.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.